Treatment with XG005 resulted in statistically significant and clinically meaningful reduction in post-surgical pain ...

BHV-2100 is under clinical development by Biohaven and currently in Phase II for Neuropathic Pain (Neuralgia).

A trial with XG005 met it's primary and secondary endpoints, demonstrating a statistically significant reduction in ...

The efficacy of pregabalin for the management of neuropathic pain associated with diabetic peripheral neuropathy has been established in several controlled clinical trials. [17,18,19] These trials ...

CFTX-1554 is under clinical development by Eli Lilly and Co and currently in Phase I for Peripheral Neuropathic Pain.

Biohaven Ltd. (NYSE: BHVN) today announced that Vlad Coric, M.D., Chairman and Chief Executive Officer, will present at the 43rd Annual J.P. Morgan Healthcare Conference at The Westin St. Francis ...

Treede RD, Jensen TS, Campbell JN, et al.: Neuropathic pain: redefinition and a grading system for clinical and research purposes. Neurology 2007; 70: 1630–5 CrossRef MEDLINE 3. Bouhassira D ...

Also Read: MIRA Pharmaceuticals’ Formulated Shows Greater Efficacy Than FDA-Approved Drug For Chemo-Induced Neuropathic Pain The ... successful clinical outcomes. The Phase 1 trial, set to ...